[CAS NO. 1629063-78-0] Ibiglustat(L-Malicacid)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1629063-78-0]

Catalog

HY-16743A

Brand

MCE

CAS

1629063-78-0

DESCRIPTION [1629063-78-0]

Overview

MDL	-
Molecular Weight	523.57
Molecular Formula	C24H30FN3O7S
SMILES	O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C.OC(C[C@H](O)C(O)=O)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]FASEB J. 2020 Dec;34(12):15922-15945.

Summary

Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease ^[1] ^[2] .

IC50 & Target

Glucosylceramide synthase ^[1] .

In Vitro

Ibiglustat (SAR402671) (1 μM, 15 days) L-Malic acid treated Fabry disease (FD) cells are close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat L-Malic acid can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05222906	Genzyme, a Sanofi Company\|Sanofi	Gaucher´s Disease Type III	April 18, 2022	Phase 3
NCT03523728	Genzyme, a Sanofi Company\|Sanofi	Polycystic Kidney, Autosomal Dominant	October 4, 2018	Phase 2\|Phase 3
NCT02843035	Genzyme, a Sanofi Company\|Sanofi	Gaucher Disease Type 1\|Gaucher Disease Type 3	January 4, 2017	Phase 2
NCT02906020	Genzyme, a Sanofi Company\|Sanofi	Parkinson´s Disease	December 15, 2016	Phase 2
NCT04221451	Genzyme, a Sanofi Company\|Sanofi	Tay-Sachs Disease Sandhoff Disease	June 29, 2020	Phase 3
NCT05238714	Genzyme, a Sanofi Company\|Sanofi	Disorders of Sphingolipid Metabolism (Healthy Volunteers)	May 26, 2020	Phase 1
NCT04705051	Sanofi	Congenital Cystic Kidney Disease	February 9, 2021	Phase 3
NCT05280548	Genzyme, a Sanofi Company\|Sanofi	Fabry´s Disease	May 3, 2022	Phase 3
NCT05206773	Genzyme, a Sanofi Company\|Sanofi	Fabry Disease	March 11, 2022	Phase 3
NCT03687554	Genzyme, a Sanofi Company\|Sanofi	Healthy Volunteers\|Polycystic Kidney, Autosomal Dominant	October 5, 2018	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 191.00 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9100 mL	9.5498 mL	19.0996 mL
5 mM	0.3820 mL	1.9100 mL	3.8199 mL
10 mM	0.1910 mL	0.9550 mL	1.9100 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

* All of the co-solvents are available by MCE.